MDS Nordion to Expand Facility to Meet Growing Demand for Medical Imaging Agent in Europe

Ottawa, Canada (ots/PRNewswire) -

- Expanded Facility in Fleurus, Belgium to be Leading Player in
Supply of Glucotrace(R) for Growing Market

MDS Nordion, a leading global provider of medical isotopes and
radiopharmaceuticals for molecular imaging, is investing U.S. $5.8
million / (euro) 4.5 million to expand its production facility in
Fleurus, Belgium to meet the growing demand for a medical imaging
agent used in cancer diagnosis and treatment. The agent, Fluorine-18
Fludeoxyglucose or FDG, is marketed and distributed by MDS Nordion
under the name Glucotrace(R). Glucotrace(R) is used in a highly
sensitive medical imaging technique called PET or Positron Emission
Tomography. As cancer rates continue to rise in Europe, the use of
PET is increasing to diagnose cancer and monitor patient progress
while in treatment.

Glucotrace(R) is a time-sensitive diagnostic pharmaceutical with a
limited lifespan. As a result, it is critical to have the ability to
reliably supply Glucotrace(R) to hospitals and clinical sites on
time. With this expansion, MDS Nordion will be able to serve more
customers within France and the Benelux Economic Union (Belgium,
Netherlands and Luxembourg).

"The new production facility will give MDS Nordion the ability to
meet increased demand from our current customers as well as extend
our market reach to new customers," said Steve West, President of
MDS Nordion. "We are committed to providing a reliable supply of
Glucotrace(R) to the medical imaging community in Europe."

Through this investment and capital upgrade, MDS Nordion will
build a larger production centre for Glucotrace(R) within its
existing facilities in Fleurus. The investment will also optimize
MDS Nordion's current resources including a higher capacity
cyclotron to produce FDG.

Presently, MDS Nordion produces Glucotrace(R) as part of a joint
venture with the University of Liège (ULG) about 80 kilometres west
of Fleurus. The new MDS Nordion facility in Fleurus, combined with
the existing site at ULG, will greatly increase production capacity
for Europe as well as provide the necessary manufacturing and supply
flexibility to serve growing market demand.

First production of Glucotrace(R) from the new facility in Fleurus
is expected to begin in mid-2008. Glucotrace(R) is approved for sale
across Europe.

About MDS Nordion

MDS Nordion (www.mds.nordion.com) is a world leader in medical
isotopes, radiation and related technologies. It is a division of MDS
Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company
that provides market-leading products and services that our
customers need for the development of drugs and diagnosis and
treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has more
than 5,600 highly skilled people in 28 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

ots Originaltext: MDS Nordion
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Media Inquiries, Olivia Nixon, MDS Nordion,
+1-(613)-592-2790 ext. 2558, +1-(613)-724-1767 (Mobile),
olivia.nixon@mdsinc.com; Investor Inquiries, Sharon Mathers,
Vice-President, Investor Relations and External Communications,
+1-(416)-675-6777 ext. 34721, sharon.mathers@mdsinc.com